NeuroOne to Host Third Quarter 2021 Earnings Call

Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on August 13, 2021, at 9:00 AM ET to discuss its financial results for the third quarter ended June 30, 2021. The company focuses on innovative surgical solutions for neurological disorders. Notably, NeuroOne successfully achieved its first performance milestone in a partnership with Zimmer Biomet, securing exclusive global distribution rights for its Evo™ patented electrode technology. The company has received FDA clearance for this technology in November 2019.

Positive

• Achieved first performance milestone with Zimmer Biomet, gaining exclusive distribution rights.
• FDA clearance for Evo cortical technology received in November 2019.

Negative

• None.

EDEN PRAIRIE, Minn., Aug. 11, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today

it will host a conference call to discuss financial results for its third quarter ended June 30, 2021, on August 13, 2021, at 9:00 AM ET.

Conference Call Information

Dial-in: (346) 248-7799
Meeting ID: 95665935395
Passcode: 902419
Webcast: https://audience.mysequire.com/webinar-view?webinar_id=ebb66f45-34a2-4d94-b4b9-f830d498fc2f

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.

The Company previously announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020 . In addition to acquiring exclusive global distribution rights to NeuroOne's Evo™ (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.

NeuroOne received FDA clearance for its Evo cortical technology in November 2019 .

In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-host-third-quarter-2021-earnings-call-301353737.html

SOURCE NeuroOne Medical Technologies Corporation

FAQ

When will NeuroOne announce its third quarter 2021 financial results?

NeuroOne will announce its third quarter 2021 financial results on August 13, 2021.

What is the primary focus of NeuroOne Medical Technologies Corporation?

NeuroOne focuses on improving surgical care for patients suffering from neurological disorders.

What technology did NeuroOne receive FDA clearance for?

NeuroOne received FDA clearance for its Evo cortical technology in November 2019.

What significant partnership does NeuroOne have?

NeuroOne has a partnership with Zimmer Biomet for the development and distribution of its Evo™ technology.

What time is the NeuroOne earnings call scheduled for?

The NeuroOne earnings call is scheduled for 9:00 AM ET on August 13, 2021.